Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 30 | 25 | −5 |
| Shares | 5.66M | 4.81M | −849.2K (−15.0%) |
| Value | $19.4M | $14.6M | −$4.79M (−24.7%) |
New holders (3)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 39,337 | $120.0K | 0.00% |
| Simplex Trading, LLC | 12,068 | $36.0K | 0.00% |
| Brave Asset Management Inc | 11,470 | $35.0K | 0.01% |
Sold out (8)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Baker Bros. Advisors LP | 184,927 | $634.0K |
| California Public Employees Retirement System | 85,232 | $292.0K |
| Renaissance Technologies LLC | 60,700 | $208.0K |
| Goldman Sachs Group Inc | 26,419 | $91.0K |
| Two Sigma Investments, LP | 16,700 | $57.0K |
| UBS Group AG | 3,418 | $12.0K |
| Capital Analysts, LLC | 882 | $3.00K |
| Reilly Financial Advisors, LLC | 250 | $1.00K |